Onyx Biotec Reports Strong Turnaround With Net Profit in H1 FY27 Results
Onyx Biotec Ltd · Outcome · 14 Nov 2026, 10:38 pm
Onyx Biotec Reports Strong Turnaround With Net Profit in H1 FY27 Results Onyx Biotec reported revenue from operations of ₹4,340.86 lakhs for the half year ended 30th Sep'26, up 25.51% YoY from ₹3,458.50 lakhs in 30th Sep'25. Net profit swung to ₹94.16 lakhs against a net loss of ₹90.05 lakhs in the previous year period, yielding a basic EPS of ₹0.52 compared to negative ₹0.50. Total expenditure stood at ₹4,253.93 lakhs, including doubtful debt provisions of ₹139.73 lakhs. Of ₹2,538.02 lakhs net IPO proceeds, ₹2,464.27 lakhs was utilized with zero deviation.
Original exchange filing (PDF)
More announcements from Onyx Biotec Ltd
- Onyx Biotec Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 · 14 Nov 2026
- VC Corporate Advisors Private Limited has Submitted to the Exchange a copy of corrigendum to the letter of offer for the attention to the public shareholders of the Onyx Biotec Limited. · 12 Nov 2026
- Onyx Biotec Limited has informed the Exchange about Board Meeting to be held on 14-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 14 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 14 Nov 2026
- VC Corporate Advisors Private Limited has Submitted to the Exchange a copy of offer opening public announcement cum corrigendum to the detailed public statement to the public shareholders of the Onyx Biotec Limited (Target Company). · 14 Oct 2026
- Onyx Biotec Limited has informed regarding Submission of the Non-Applicability of the provisions relating to Corporate Governance as specified in the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. · 14 Oct 2026
- Onyx Biotec Limited has Submitted to the Exchange a newspaper copy of the Recommendation of the Independent Director Committee ("IDC") of the company in relation to the Open Offer made by Mr. Kunal Bhardwaj ( Acquirer 1 ), Mr. Gautam Bhardwaj ( Acquirer 2 ), Mr. Kanhaiya Bhardwaj ( Acquirer 3 ) and Mr. Kapil Bhardwaj ( Acquirer 4 ) (hereinafter collectively referred to as the Acquirers ) to the public shareholders of the company under Regulation 26(7) of SEBI (SAST) Regulations, 2011 and subseq · 08 Oct 2026
- Onyx Biotec Limited has Submitted to the Exchange the outcome of the meeting of the committee of the Independent Directors held today i.e. October 07, 2026 to give their recomendation in the Open Offer of Onyx Biotec Limited in compliance with Regulation 26(7) of the SEBI (SAST) Regulations, 2011and subsequent Amendments thereto. · 08 Oct 2026
